menu
    • menu
    [{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Aixial Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F Flotufolastat","moa":"PSMA","graph1":"Oncology","graph2":"Phase IV","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Aixial Group","highestDevelopmentStatusID":"11","companyTruncated":"Blue Earth Diagnostics \/ Aixial Group"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F rhPSMA-7.3","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"18-F rhPSMA-7.3","moa":"PSMA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"1","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3 (18F)","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"}]

    Find Clinical Drug Pipeline Developments & Deals by Blue Earth Diagnostics

    Menu

    Blue Earth Diagnostics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F rhPSMA-7.3

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Hackensack Meridian Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

                            Details : 18-F rhPSMA-7.3 is a Radiolabelled Compounds drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 08, 2025

                            Lead Product(s) : 18-F rhPSMA-7.3

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Hackensack Meridian Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F rhPSMA-7.3

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : AdventHealth

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

                            Details : 18-F rhPSMA-7.3 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 27, 2024

                            Lead Product(s) : 18-F rhPSMA-7.3

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : AdventHealth

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F Flotufolastat

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Aixial Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in ...

                            Details : 18-F Flotufolastat is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : 18-F Flotufolastat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Aixial Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Brigham and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

                            Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 02, 2023

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Brigham and Women's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Baptist Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

                            Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 21, 2023

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Baptist Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human PSMA-7.3 (18F)

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : MidLantic Urology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Ass...

                            Details : Recombinant Human PSMA-7.3 (18F) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 05, 2023

                            Lead Product(s) : Recombinant Human PSMA-7.3 (18F)

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : MidLantic Urology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Baptist Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

                            Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 26, 2022

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Baptist Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Baptist Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radio...

                            Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 30, 2020

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Baptist Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Precision For Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

                            Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 01, 2020

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Precision For Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed

                            Blue Earth Diagnostics

                            United Kingdom arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Precision For Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metasta...

                            Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            June 01, 2020

                            Lead Product(s) : 18-F Fluciclovine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Precision For Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth